Q32 Bio Debt/EBITDA

What does Q32 Bio do? Homology Medicines, Inc. generates revenue by developing and commercializing treatments for rare diseases at the genetic level. The company operates as a technology platform focused on creating a pipeline of new medicines that address and cure the underlying cause of monogenic diseases. Its lead product candidate, HMI-102, is a gene therapy designed for the treatment of phenylketonuria (PKU), with the PKU program specifically targeting adults using this gene therapy approach. The firm utilizes its suite of 15 adeno-associated virus vectors (AAVHSCs) to enable a method of gene editing called gene correction, allowing for precise targeting of disease-relevant tissues across both gene editing and gene therapy modalities. Q32 Bio is one of the most popular companies on Eulerpool.